vs

Side-by-side financial comparison of American Outdoor Brands, Inc. (AOUT) and Ginkgo Bioworks Holdings, Inc. (DNA). Click either name above to swap in a different company.

American Outdoor Brands, Inc. is the larger business by last-quarter revenue ($57.2M vs $33.4M, roughly 1.7× Ginkgo Bioworks Holdings, Inc.). On growth, American Outdoor Brands, Inc. posted the faster year-over-year revenue change (-5.0% vs -23.8%). American Outdoor Brands, Inc. produced more free cash flow last quarter ($-14.1M vs $-47.7M). Over the past eight quarters, American Outdoor Brands, Inc.'s revenue compounded faster (3.5% CAGR vs -6.2%).

Deckers Outdoor Corporation, doing business as Deckers Brands, is an American footwear designer and distributor founded in 1973 and based in Goleta, California. The company's portfolio of brands includes UGG, Teva, and Hoka. It was founded by Doug Otto and Karl F. Lopker.

Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It...

AOUT vs DNA — Head-to-Head

Bigger by revenue
AOUT
AOUT
1.7× larger
AOUT
$57.2M
$33.4M
DNA
Growing faster (revenue YoY)
AOUT
AOUT
+18.8% gap
AOUT
-5.0%
-23.8%
DNA
More free cash flow
AOUT
AOUT
$33.6M more FCF
AOUT
$-14.1M
$-47.7M
DNA
Faster 2-yr revenue CAGR
AOUT
AOUT
Annualised
AOUT
3.5%
-6.2%
DNA

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
AOUT
AOUT
DNA
DNA
Revenue
$57.2M
$33.4M
Net Profit
$2.1M
Gross Margin
45.6%
Operating Margin
3.7%
-211.9%
Net Margin
3.6%
Revenue YoY
-5.0%
-23.8%
Net Profit YoY
-33.3%
EPS (diluted)
$0.16
$-1.41

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AOUT
AOUT
DNA
DNA
Q4 25
$57.2M
$33.4M
Q3 25
$29.7M
$38.8M
Q2 25
$61.9M
$49.6M
Q1 25
$58.5M
$48.3M
Q4 24
$60.2M
$43.8M
Q3 24
$41.6M
$89.0M
Q2 24
$46.3M
$56.2M
Q1 24
$53.4M
$37.9M
Net Profit
AOUT
AOUT
DNA
DNA
Q4 25
$2.1M
Q3 25
$-6.8M
$-80.8M
Q2 25
$-992.0K
$-60.3M
Q1 25
$169.0K
$-91.0M
Q4 24
$3.1M
Q3 24
$-2.4M
$-56.4M
Q2 24
$-5.3M
$-217.2M
Q1 24
$-2.9M
$-165.9M
Gross Margin
AOUT
AOUT
DNA
DNA
Q4 25
45.6%
Q3 25
46.7%
Q2 25
40.9%
Q1 25
44.7%
Q4 24
48.0%
Q3 24
45.4%
Q2 24
41.9%
Q1 24
42.7%
Operating Margin
AOUT
AOUT
DNA
DNA
Q4 25
3.7%
-211.9%
Q3 25
-23.0%
-231.8%
Q2 25
-1.5%
-132.1%
Q1 25
0.5%
-184.1%
Q4 24
5.1%
-236.3%
Q3 24
-6.2%
-62.0%
Q2 24
-11.9%
-396.7%
Q1 24
-5.4%
-469.1%
Net Margin
AOUT
AOUT
DNA
DNA
Q4 25
3.6%
Q3 25
-23.0%
-207.9%
Q2 25
-1.6%
-121.6%
Q1 25
0.3%
-188.2%
Q4 24
5.2%
Q3 24
-5.7%
-63.3%
Q2 24
-11.5%
-386.4%
Q1 24
-5.4%
-437.3%
EPS (diluted)
AOUT
AOUT
DNA
DNA
Q4 25
$0.16
$-1.41
Q3 25
$-0.54
$-1.45
Q2 25
$-0.08
$-1.10
Q1 25
$0.01
$-1.68
Q4 24
$0.24
$-1.91
Q3 24
$-0.18
$-1.08
Q2 24
$-0.41
$-4.23
Q1 24
$-0.23
$-3.32

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AOUT
AOUT
DNA
DNA
Cash + ST InvestmentsLiquidity on hand
$3.1M
$422.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$170.4M
$508.6M
Total Assets
$240.9M
$1.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AOUT
AOUT
DNA
DNA
Q4 25
$3.1M
$422.6M
Q3 25
$17.8M
$495.5M
Q2 25
$23.4M
$559.4M
Q1 25
$17.1M
$325.3M
Q4 24
$14.2M
$561.6M
Q3 24
$23.5M
$616.2M
Q2 24
$29.7M
$730.4M
Q1 24
$15.9M
$840.4M
Stockholders' Equity
AOUT
AOUT
DNA
DNA
Q4 25
$170.4M
$508.6M
Q3 25
$167.8M
$559.8M
Q2 25
$177.6M
$613.0M
Q1 25
$178.7M
$647.4M
Q4 24
$178.9M
$716.1M
Q3 24
$175.7M
$797.9M
Q2 24
$177.9M
$833.1M
Q1 24
$182.4M
$987.3M
Total Assets
AOUT
AOUT
DNA
DNA
Q4 25
$240.9M
$1.1B
Q3 25
$241.9M
$1.2B
Q2 25
$246.4M
$1.2B
Q1 25
$245.9M
$1.3B
Q4 24
$254.1M
$1.4B
Q3 24
$244.8M
$1.5B
Q2 24
$240.6M
$1.6B
Q1 24
$239.1M
$1.6B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AOUT
AOUT
DNA
DNA
Operating Cash FlowLast quarter
$-13.3M
$-47.7M
Free Cash FlowOCF − Capex
$-14.1M
$-47.7M
FCF MarginFCF / Revenue
-24.6%
-142.8%
Capex IntensityCapex / Revenue
1.3%
0.0%
Cash ConversionOCF / Net Profit
-6.41×
TTM Free Cash FlowTrailing 4 quarters
$-4.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AOUT
AOUT
DNA
DNA
Q4 25
$-13.3M
$-47.7M
Q3 25
$-1.7M
$-31.6M
Q2 25
$7.8M
$-40.3M
Q1 25
$5.9M
$-51.5M
Q4 24
$-7.9M
$-42.4M
Q3 24
$-4.4M
$-103.5M
Q2 24
$14.7M
$-84.4M
Q1 24
$13.0M
$-89.3M
Free Cash Flow
AOUT
AOUT
DNA
DNA
Q4 25
$-14.1M
$-47.7M
Q3 25
$-2.0M
Q2 25
$7.2M
$-40.3M
Q1 25
$4.2M
$-59.1M
Q4 24
$-8.0M
$-56.1M
Q3 24
$-5.2M
$-118.6M
Q2 24
$14.2M
$-111.4M
Q1 24
$9.7M
$-96.0M
FCF Margin
AOUT
AOUT
DNA
DNA
Q4 25
-24.6%
-142.8%
Q3 25
-6.7%
Q2 25
11.6%
-81.2%
Q1 25
7.2%
-122.4%
Q4 24
-13.3%
-128.0%
Q3 24
-12.5%
-133.2%
Q2 24
30.6%
-198.2%
Q1 24
18.2%
-252.9%
Capex Intensity
AOUT
AOUT
DNA
DNA
Q4 25
1.3%
0.0%
Q3 25
1.0%
0.0%
Q2 25
0.9%
0.1%
Q1 25
2.9%
15.8%
Q4 24
0.1%
31.3%
Q3 24
2.0%
16.9%
Q2 24
1.1%
48.1%
Q1 24
6.2%
17.7%
Cash Conversion
AOUT
AOUT
DNA
DNA
Q4 25
-6.41×
Q3 25
Q2 25
Q1 25
34.86×
Q4 24
-2.55×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AOUT
AOUT

Traditional Channels Net Sales$36.8M64%
E Commerce Channels Net Sales$20.4M36%

DNA
DNA

Cell Engineering Segment$26.0M78%
Other$7.4M22%

Related Comparisons